Collaboration will apply Cellares' Cell Shuttle and Cell Q platforms to TSC-101 as a potentially scalable and cost-efficient path to commercialization.
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary and nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
QCL is a CDMO privately owned and operated since 1998. We excel in pre-formulation, formulation development, and delivering early phase clinical trial materials on aggressive timelines. We provide analytical development and validation, stability studies, and testing of small and large molecule APIs, finished products, and raw materials. New construction doubles our footprint to 200,000 sq. ft., expanding services into late phase clinical and small scale commercial GMP manufacturing including state of the art sterile fill-finish for both small and large molecules.
